Clinical Trial

Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 6, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis. To evaluate the safety of IxCell hUC-MSC-O in the treatment of patients with knee osteoarthritis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-03.
Trial Details
NCT Number NCT06716281
Lead Sponsor Shanghai IxCell Biotechnology Co., LTD
Conditions Knee Osteoarthritis
Enrollment 398 participants
Start Date 2024-01-05
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-06